Develops therapeutics for neurological disorders. Focuses on epilepsy and other neurological conditions. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 20% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 755.9× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 52% of them.
Analysts' average target sits 29% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades 17% below its peak. The market has trimmed its expectations for the company.
The company sells $7.5M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $345.9M against $7.5M in annual sales.
At the current pace of spending, the cash lasts about 1.6 years. After that, the company needs to find new money.
On our five-subject report card, XENE sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: XENE’s sales are going backwards, and it closed last year at a loss. The road back runs through both.
Analysts’ average target sits above today’s price, yet the valuation grade (52/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.